8QPR

SARS-CoV-2 S protein bound to human neutralising antibody UZGENT_G5

Summary for 8QPR

• Entry DOI: 10.2210/pdb8qpr/pdb
• EMDB information: 18560
• Descriptor: Spike glycoprotein,Fibritin, IgG light chain - FAB, IgG heavy chain - FAB, ... (5 entities in total)
• Functional Keywords: neutralizing antibody, spike protein, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); More
• Total number of polymer chains: 3
• Total formula weight: 192675.81

Authors

Remaut, H.,Reiter, D.,Vandenkerckhove, L.,Acar, D.D.,Witkowski, W.,Gerlo, S. (deposition date: 2023-10-03, release date: 2024-01-31, Last modification date: 2024-11-06)

Primary citation

Acar, D.D.,Witkowski, W.,Wejda, M.,Wei, R.,Desmet, T.,Schepens, B.,De Cae, S.,Sedeyn, K.,Eeckhaut, H.,Fijalkowska, D.,Roose, K.,Vanmarcke, S.,Poupon, A.,Jochmans, D.,Zhang, X.,Abdelnabi, R.,Foo, C.S.,Weynand, B.,Reiter, D.,Callewaert, N.,Remaut, H.,Neyts, J.,Saelens, X.,Gerlo, S.,Vandekerckhove, L.
Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted.
Ebiomedicine, 100:104960-104960, 2024

PubMed Abstract: SARS-CoV-2-neutralizing antibodies (nABs) showed great promise in the early phases of the COVID-19 pandemic. The emergence of resistant strains, however, quickly rendered the majority of clinically approved nABs ineffective. This underscored the imperative to develop nAB cocktails targeting non-overlapping epitopes.

PubMed: 38232633
DOI: 10.1016/j.ebiom.2023.104960

Experimental method

ELECTRON MICROSCOPY (3.8 Å)